Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
More than 20 years ago, GLP-1 receptor agonists entered the market as type 2 diabetes therapies, building steady commercial success on the strength of durable A1C reduction, once-weekly dosing, and…
Portfolio contracting is quietly rewriting the rules of pharmaceutical market access. What began as a way to bundle a handful of related products has evolved into a defining access strategy…
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read on for key insights into the year…
The mental health treatment landscape is evolving rapidly, driven by new and innovative therapies. Recent approvals like KarXT (from Karuna Therapeutics, now part of Bristol Myers Squibb) for schizophrenia, as…
Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed condition affecting millions worldwide. People with OSA are subject to sudden drops in blood oxygenation levels that can lead to severe…
As the pharma industry continues to adjust to the provisions of the Inflation Reduction Act (IRA), the country will soon be ushering in a new presidential administration—leaving the future of…
Initially developed to manage type 2 diabetes, glucagon-like peptide-1 (GLP-1) agonist medications have become exceptionally popular for weight loss. High-profile celebrity endorsements and widespread media coverage has led to an…
We are in the midst of a weight-loss drug explosion. Mania for Novo Nordisk’s Wegovy/Ozempic has taken hold of both celebrities and everyday patients, leading to massive shortages and a…
At the beginning of May, almost 8,000 attendees descended on Las Vegas for Asembia’s AXS24 Summit. While all of the session speakers discussed the future of healthcare in one way…
As healthcare costs continue to climb, insurers are eager to control their spend. According to WTW’s Global Medical Trends Survey, 58% of insurers anticipate higher medical trend over the next…
